Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc demonstrates a strong potential for growth through its innovative pipeline, particularly highlighted by the promising efficacy and safety profile of A-005 in multiple sclerosis, which could translate to significant clinical advancements in targeted therapies. The company’s ongoing data improvements, especially with ESK-001 in psoriasis, suggest the possibility of outperforming existing market leaders such as OTEZLA, further enhancing its revenue prospects. Additionally, the confidence expressed by Acelyrin's board regarding the merger indicates a strategic alignment aimed at maximizing long-term value, reinforcing a positive outlook for shareholders of Alumis.

Bears say

Alumis Inc faces significant risks that could adversely impact its financial outlook, primarily centered on the advancement and efficacy of its lead product candidate, ESK-001. Key concerns include the potential inability to progress ESK-001 to pivotal trials timely, failure to demonstrate clinical efficacy, and delays in obtaining regulatory approvals in major markets, all of which could stifle revenue generation. Additionally, the company is subject to intense competition in the immunology and inflammation (I&I) therapeutic space, which could hinder market acceptance and lead to possible dilution risks for current shareholders.

Alumis Inc (ALMS) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 7 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.